Drug intelligence / Profile preview

RBM-003

Development stage: Preclinical
Lead developer: Ribomic
Modality: RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules

Overview

RBM-003 is a strong and specific RNA aptamer inhibitor of chymase, a chymotrypsin-like serine protease stored in mast cell granules. Chymase becomes active in damaged tissues, where it cleaves pro-proteins to their active forms, contributing to organ dysfunction such as heart failure. By inhibiting chymase, RBM-003 has demonstrated significant improvement in cardiac function and survival rates in animal models of myocardial infarction (MI). The drug is being developed primarily for the treatment of acute heart failure and other cardiovascular diseases[1][2][5].

Targets

CMA1 (Chymase)

Beyond the preview

Go deeper on RBM-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBM-003.

Explore the full profile